An interventional study of Chamomile (Matricaria recutita) and Chamomile in Primary Dysmenorrhea, sponsored by Universiti Tunku Abdul Rahman. Recruiting at 1 site in Malaysia. Open to female participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2025-07-30.
Sponsored by Universiti Tunku Abdul Rahman · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate the effects of a beverage containing chamomile and L-theanine on menstrual symptoms, pain intensity, mood, and sleep quality among young adult females with primary dysmenorrhea.
This study aims to evaluate the effects of a beverage containing chamomile and L-theanine on menstrual symptoms, pain intensity, mood, and sleep quality among young adult females with primary dysmenorrhea.
432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.
This study's planned enrollment of 30 is below the median of 62 across 364 interventional studies indexed under Dysmenorrhea.
Browse Dysmenorrhea studies →Universiti Tunku Abdul Rahman is the lead sponsor of 37 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in the intervention group will consume a chamomile with L-theanine (CTT) beverage, which contains 480 mg of chamomile extract and 200 mg of L-theanine.
Dietary Supplement: Chamomile (Matricaria recutita)
Participants in the control group will consume a chamomile-flavored beverage (non-CTT), which is flavored with commercial chamomile flavoring.
Dietary Supplement: Chamomile
Participants in the intervention group will consume the chamomile with L-theanine (CTT) beverage, which contains 480 mg of chamomile extract and 200 mg of L-theanine.
A chamomile-flavored beverage
Also known as: Chamomile flavored beverage
Pain intensity
The pain intensity is assessed using the Visual Analogue Scale (VAS) and the Numeric Rating Scale (NRS). Participants mark the point on the scale (0 to 10) that best represents the average intensity of their menstrual pain. A higher score on the VAS and NRS indicates greater pain intensity.
Time frame: 2 months
Menstrual symptoms
The Cox Menstrual Symptom Scale (CMSS) is used to assess the severity of menstrual-related symptoms experienced by participants during their most recent menstrual cycle. Each item in the CMSS is rated on a scale from 0 (not noticeable), 1 (slightly bothersome), 2 (moderately bothersome), 3 (severely bothersome), to 4 (very severely bothersome).
Time frame: 2 months
Sleep quality
The Pittsburgh Sleep Quality Index (PSQI) is used to assess the sleep quality of participants during the past week. The total PSQI score ranges from 0 to 21, with higher scores indicating poorer sleep quality.
Time frame: 2 months
Mood
The Profile of Mood States (POMS) is used to assess six mood subscales (vigor, tension, depression, anger, fatigue, and confusion) of participants during the past week. Each item is rated on a 5-point Likert scale, ranging from 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a lot), and 4 (extremely).
Time frame: 2 months
Hemoglobin
Hemoglobin is measured in mmol/L
Time frame: 2 months
Plan to share: Undecided — This project is financially supported by a beverage company and may contain commercially sensitive data. If other researchers require the IPD, they must obtain approval from the beverage company through the principal investigator.
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Jul 2025, 4 months after the start.
Of 179 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 4 months is below that.
Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 3 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Matricaria recutita
Universiti Tunku Abdul Rahman